EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T

Alexander Gäble, Alexander Dierks, Andreas Rinscheid, Marianne Patt, Georgine Wienand, Christian H Pfob, Malte Kircher, Kazuhito Fukushima, Ana Antić Nikolić, Johanna S Enke, Tilman Janzen, Julie Steinestel und 5 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-06959-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Alexander Gäble und 16 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Lutetium, Radioisotopes, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Augsburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Radioligand therapy is an increasingly important option for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). Radiohybrid ligands targeting prostate-specific membrane antigen (PSMA) are a novel group of theranostic radioligand therapy agents for which higher tumour absorbed radiation doses have been demonstrated compared to established PSMA ligands. Here, we report data from ten patients who were treated within a compassionate use program with the radiohybrid PSMA-ligand [ 177 Lu]Lu-rhPSMA-10.1 after experiencing disease progression under treatment with [ 177 Lu]Lu-PSMA-I&T.

Methods

Ten patients with advanced PSMA-positive prostate cancer who showed progression under treatment with [ 177 Lu]Lu-PSMA-I&T received up to three cycles of rescue therapy with [ 177 Lu]Lu-rhPSMA-10.1 (7.4–8.1 GBq per cycle). Efficacy (PSA response according to PCWG3 and RECIP) and overall survival were evaluated. Adverse events were recorded from first application.

Results

Despite progression with [ 177 Lu]Lu-PSMA-I&T, after the first cycle of [ 177 Lu]Lu-rhPSMA-10.1 rescue therapy, five patients (50%) showed a decrease in serum PSA level. In imaging, three of the ten patients (30%) showed a partial radiologic response. Four of the five patients with a decrease of serum PSA under [ 177 Lu]Lu-rhPSMA-10.1 had initially responded to treatment with [ 177 Lu]Lu-PSMA-I&T but had become resistant. However, the remaining patient had shown continuous disease progression during [ 177 Lu]Lu-PSMA-I&T therapy but showed an immediate response to [ 177 Lu]Lu-rhPSMA-10.1. The additional treatment with [ 177 Lu]Lu-rhPSMA-10.1 was generally well tolerated by all patients.

Conclusions

Patients showing tumour progression while receiving [ 177 Lu]Lu-PSMA-I&T radioligand therapy may benefit from rescue therapy with the novel radiohybrid PSMA ligand, [ 177 Lu]Lu-rhPSMA-10.1. Higher tumour absorbed radiation doses with [ 177 Lu]Lu-rhPSMA-10.1 may overcome primary and acquired radiation resistance. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumRadioisotopesGlutamate Carboxypeptidase IIAntigens, SurfaceProstatic Neoplasms, Castration-ResistantDrug Resistance, NeoplasmAntineoplastic AgentsHumansMaleRecombinant ProteinsSalvage TherapyNeoplasm MetastasisPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

Prostate cancerProstate-specific membrane antigenRadiohybrid ligandsRadioligand therapyTherapeutic response

Substanzen

Lutetium-177LutetiumRadioisotopesRecombinant ProteinsFOLH1 protein, humanGlutamate Carboxypeptidase IIAntigens, SurfaceAntineoplastic Agents

Autor:innen und Institutionen

  • Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
  • Bavarian Cancer Research Center (BZKF), Augsburg, Germany.
  • Medical Physics and Radiation Protection, University Hospital Augsburg, Augsburg, Germany.
  • Radiology, Kobe International Collaboration Clinic, Kobe, Japan.
  • Urology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
  • Internal Medicine, Oncology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.

ORCID-Profile: Ralph A Bundschuh

Förderung

  • Universitätsklinikum Augsburg

Zitieren

APA

Gäble, A., Dierks, A., Rinscheid, A., Patt, M., Wienand, G., Pfob, C. H., Kircher, M., Fukushima, K., Nikolić, A. A., Enke, J. S., Janzen, T., Steinestel, J., Kempter, H., Trepel, M., Weckermann, D., Lapa, C., & Bundschuh, R. A. (2025). Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06959-5

Vancouver

Gäble A, Dierks A, Rinscheid A, Patt M, Wienand G, Pfob CH, et al. Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06959-5

BibTeX
@article{Gble2025,
  author = {Gäble, Alexander and Dierks, Alexander and Rinscheid, Andreas and Patt, Marianne and Wienand, Georgine and Pfob, Christian H and Kircher, Malte and Fukushima, Kazuhito and Nikolić, Ana Antić and Enke, Johanna S and Janzen, Tilman and Steinestel, Julie and Kempter, Hildegard and Trepel, Martin and Weckermann, Dorothea and Lapa, Constantin and Bundschuh, Ralph A},
  title = {Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-06959-5}
}
Kostenlos starten →